The perfused liver utilisation study (PLUS): challenges and innovation in the evaluation of an emerging technology
Transplant International · 08.09.2026 · 39
DOI: 10.3389/ti.2026.16653 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, online erschienen am 08.09.2026. Verfasst von Simon Robert Knight und 29 weiteren Autor:innen. Beteiligte Einrichtung: University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Liver Transplantation, Perfusion, Organ Preservation, Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.
Abstract (Originalsprache)
Previous studies suggest that donor liver normothermic machine perfusion (NMP) reduces injury and enables functional assessment, resulting in an increase in utilisation. The PLUS study was designed to assess the impact of NMP availability on utilisation of livers at high risk of non-use. Using a threshold-crossing design, functional utilisation was assessed in a real-world retrospective registry-based control cohort. A predetermined efficacy threshold was set, and a prospective cohort was recruited in all UK liver transplant centres with NMP made available for all livers at high risk of non-utilisation. Availability of NMP resulted in a significant increase in functional utilisation (OR: 1.26, 95% CI: 1.04–1.53), but this did not exceed the pre-determined efficacy threshold. The threshold was exceeded in the subgroup of donation after circulatory death (DCD) livers, although this increase was reduced with adjustment for the use of normothermic regional perfusion. NMP was used in only 31% of retrieved livers, with variation between centres. The benefit of having NMP available was less than anticipated, likely due to low use in some centres associated with staff availability. Provision of NMP as a service, or centralisation of NMP use in assessment and recovery centres, may improve uptake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Oxford, Oxford, United Kingdom.
- NHS Blood and Transplant, Bristol, United Kingdom.
- University of Cambridge, Cambridge, United Kingdom.
- University College London, London, United Kingdom.
- Royal Free London NHS Foundation Trust, London, United Kingdom.
- Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Förderung
- National Institute for Health and Care Research
Zitieren
APA
Knight, S. R., Thomas, H. L., Brown, R., Brown, C., Brusby, K., Arbon, E., Silsby, L., Newton, A., Mehew, J., Iqbal, A., Keen, K., Bahar, S., Watson, C., Davidson, B., Nasralla, D., Ceresa, C., Fiore, B., Sherif, A. E., Wilson, C., …, & Friend, P. J. (2026). The perfused liver utilisation study (PLUS): challenges and innovation in the evaluation of an emerging technology. Transplant International, 39. https://doi.org/10.3389/ti.2026.16653
Vancouver
Knight SR, Thomas HL, Brown R, Brown C, Brusby K, Arbon E, et al. The perfused liver utilisation study (PLUS): challenges and innovation in the evaluation of an emerging technology. Transplant International. 2026;39. doi:10.3389/ti.2026.16653
BibTeX
@article{Knight2026,
author = {Knight, Simon Robert and Thomas, Helen L and Brown, Rosemary and Brown, Charlie and Brusby, Kerrie and Arbon, Emily and Silsby, Laura and Newton, Alice and Mehew, Jennifer and Iqbal, Aleema and Keen, Katie and Bahar, Syeda and Watson, Christopher and Davidson, Brian and Nasralla, David and Ceresa, Carlo and Fiore, Barbara and Sherif, Ahmed E and Wilson, Colin and Mahendran, Balaji and Pollok, Joerg-Matthias and Mateos, Rebeca S and Jassem, Wayel and Gaurav, Rohit and Oniscu, Gabriel C and Marshall, Craig and Hann, Angus and Ravikumar, Reena and Coussios, Constantin and Friend, Peter J},
title = {The perfused liver utilisation study (PLUS): challenges and innovation in the evaluation of an emerging technology},
journal = {Transplant International},
year = {2026},
volume = {39},
doi = {10.3389/ti.2026.16653}
}
EUVIMED